Promoting Generic Drug Use and Initiatives for Home Healthcare
First written in FY2016. 19 of 31 entries say "Advanced", first in FY2020-Q1. Latest entry: 2026-11-10.
0 other companies' latest entry also says "Advanced".
- 2026-11-10AdvancedEarnings presentation materials
「取引店舗数が順調に拡大し、前年同期比＋23.0%」
後発医薬品の取引店舗数は10,124店舗まで拡大した。一方、販売終了により取扱品目数は126品目となった。 - FY2026AdvancedAnnual report
「The pharmaceutical manufacturing and sales division worked to develop new business partners, resulting in steady growth in the number of customer stores, which reached 9,082, an increase of 1,901 stores from the end of the same period of the previous year. As of 31 March 2026, it was selling 56 active ingredients across 130 products.」
The number of customer stores expanded to 9,082 through the development of new business partners, while the sales scale expanded to 56 active ingredients across 130 products. Meanwhile, 10 active ingredients across 20 products were subject to shipment adjustments. - FY2026-H1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division worked to develop new business partners, resulting in steady growth in the number of customer stores, which reached 7,823, an increase of 2,123 stores from the end of the same period of the previous year. As of 30 September 2025, it was selling 52 active ingredients across 120 products, including 6 active ingredients across 11 products subject to shipment adjustments.」
The number of customer stores for generic drugs expanded to 7,823 through the development of new business partners. The product lineup comprised 52 active ingredients across 120 products, with 6 active ingredients across 11 products subject to shipment adjustments. - FY2025AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 52 active ingredients across 120 products as of 31 March 2025, including 3 active ingredients across 6 products subject to shipment adjustments. The number of new customer stores during the consolidated fiscal year progressed steadily, reaching 7,181 as of 31 March 2025, an increase of 2,183 stores year on year.」
The scale of generic drug sales reached 52 active ingredients across 120 products, while the number of customer stores increased to 7,181. Meanwhile, 3 active ingredients across 6 products were reported to be subject to shipment adjustments. - FY2025-H1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 49 active ingredients across 113 products as of 30 September 2024, including 3 active ingredients across 6 products subject to shipment adjustments. The number of new customer stores during the six-month interim consolidated period progressed steadily, reaching 5,700 as of 30 September 2024, an increase of 1,806 stores from the end of the same period of the previous year.」
The scale of generic drug sales expanded from 47 active ingredients across 98 products to 49 active ingredients across 113 products, while the number of customer stores increased to 5,700, up 1,806 stores from the end of the same period of the previous year. Meanwhile, 3 active ingredients across 6 products were reported to be subject to shipment adjustments. - FY2024-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 47 active ingredients across 98 products as of 30 September 2023. Although orders for some products had been suspended due to shipment adjustments, the number of new customer stores during the second quarter progressed steadily, reaching 3,894 as of 30 September 2023, an increase of 663 stores year on year.」
The scale of generic drug sales expanded from 41 active ingredients across 82 products at the end of the previous fiscal year to 47 active ingredients across 98 products, and the number of customer stores increased to 3,894. Meanwhile, the suspension of orders for some products due to shipment adjustments was reported. - FY2024-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 46 active ingredients across 96 products as of 30 June 2023.」
The scale of generic drug sales expanded from 41 active ingredients across 82 products at the end of the previous fiscal year to 46 active ingredients across 96 products. - FY2023-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 44 active ingredients across 90 products as of 31 December 2022. In addition to the Group's pharmacies, the number of stores with which it did business reached 2,042 general member pharmacies, an increase of 344 stores from the end of the previous consolidated fiscal year.」
The scale of generic drug sales expanded from 41 active ingredients across 82 products at the end of the previous fiscal year to 44 active ingredients across 90 products, while the number of stores with which general member pharmacies did business also increased by 344. - FY2023-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division was selling 42 active ingredients across 85 products as of 30 September 2022. In addition to the Group's pharmacies, the number of stores with which it did business reached 1,886 general member pharmacies, an increase of 188 stores from the end of the previous consolidated fiscal year.」
The scale of generic drug sales expanded from 41 active ingredients across 82 products at the end of March 2022 to 42 active ingredients across 85 products, while the number of stores with which general member pharmacies did business also increased by 188. - FY2022AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 7 active ingredients across 14 products during the fiscal year and, as of 31 March 2022, was selling 41 active ingredients across 82 products.」
7 active ingredients across 14 generic drug products were newly launched, expanding the sales scale to 41 active ingredients across 82 products. - FY2022-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 7 active ingredients across 12 products during the first 9 months of the fiscal year and, as of 31 December 2021, was selling 41 active ingredients across 80 products.」
7 active ingredients across 12 generic drug products were newly launched, expanding the sales scale to 41 active ingredients across 80 products. - FY2022-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 5 active ingredients across 9 products during the first 6 months of the fiscal year and, as of 30 September 2021, was selling 39 active ingredients across 77 products.」
5 active ingredients across 9 generic drug products were newly launched, expanding the sales scale to 39 active ingredients across 77 products. - FY2022-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division launched 3 active ingredients across 6 products in June 2021 and, as of 30 June 2021, was selling 37 active ingredients across 74 products.」
3 active ingredients across 6 generic drug products were newly launched, expanding the sales scale to 37 active ingredients across 74 products. - FY2021AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs, and sales are growing steadily, including following the launch of 11 active ingredients across 17 products during the fiscal year. As of 31 March 2021, it was selling 34 active ingredients across 68 products and will continue to expand its product lineup further.」
During the fiscal year, 11 active ingredients across 17 generic drug products were launched, expanding the sales scale to 34 active ingredients across 68 products. - FY2021-Q3RestatedAnnual report
「The company worked to improve productivity and reduce expenses by promoting the switch to generic drugs offering stable supply and economic benefits, improving operational efficiency, optimizing staffing levels, reducing overtime, and taking other measures.」
Continuing the switch to generic drugs, optimization of staffing levels, reduction of overtime, improvement of operational efficiency and productivity, and expense reductions. - FY2021-Q2AdvancedAnnual report
「Although affected by a decline in the number of prescriptions filled in the dispensing pharmacy division, the company worked to improve productivity and reduce expenses by promoting the switch to generic drugs offering stable supply and economic benefits, improving operational efficiency, optimizing staffing levels, reducing overtime, and taking other measures.」
Promoting the switch to generic drugs in conjunction with optimized staffing levels, reduced overtime, improved operational efficiency, higher productivity, and expense reductions. - FY2021-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division continues to work to ensure a stable supply of high-quality, low-cost generic drugs. As of 30 June 2020, it was selling 29 active ingredients across 60 products, and the number of stores handling products at general member pharmacies in the pharmaceutical network had reached 707.」
The scale of generic drug sales expanded from 23 active ingredients across 51 products to 29 active ingredients across 60 products, and the 707 stores handling products at general member pharmacies were also reported. - FY2020-Q3AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs and, as of 31 December 2019, was selling 23 active ingredients across 51 products.」
The scale of generic drug sales expanded from 20 active ingredients across 45 products at the end of September 2019 to 23 active ingredients across 51 products. - FY2020-Q2AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs and, as of 30 September 2019, was selling 20 active ingredients across 45 products.」
The scale of generic drug sales expanded from 18 active ingredients across 39 products at the end of June 2019 to 20 active ingredients across 45 products. - FY2020-Q1AdvancedAnnual report
「The pharmaceutical manufacturing and sales division is working to ensure a stable supply of high-quality, low-cost generic drugs and, as of 30 June 2019, was selling 18 active ingredients across 39 products.」
The scale of generic drug sales expanded from 17 active ingredients across 34 products at the end of March 2019 to 18 active ingredients across 39 products. - FY2019-Q3RestatedAnnual report
「The Group continues to promote home healthcare initiatives and the provision of services as family pharmacists and family pharmacies, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and the provision of family pharmacist and family pharmacy functions. - FY2019-Q2RestatedAnnual report
「The Group continues to promote home healthcare initiatives and the provision of services as family pharmacists and family pharmacies, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and the provision of family pharmacist and family pharmacy functions. - FY2019-Q1RestatedAnnual report
「The Group continues to promote home healthcare initiatives and the provision of services as family pharmacists and family pharmacies, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and the provision of family pharmacist and family pharmacy functions. - FY2018RaisedAnnual report
「We will expand the manufacture and sale of high-quality generic drugs, contributing to the government's efforts to promote the use of generic drugs and achieve efficient pharmaceutical distribution.」
The scope of measures expanded from promoting the use of conventional generic drugs to expanding the manufacture and sale of generic drugs through Felsen Pharma. Strengthening home healthcare and health support functions was also included. - FY2018-Q3RestatedAnnual report
「The Group is promoting home healthcare initiatives and the provision of services as family pharmacists and family pharmacies, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and the provision of family pharmacist and family pharmacy functions. - FY2018-Q2RestatedAnnual report
「The Group is promoting home healthcare initiatives and the provision of services as family pharmacists and family pharmacies, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and the provision of family pharmacist and family pharmacy functions. - FY2017RestatedAnnual report
「The company is promoting home healthcare initiatives and the provision of services as family pharmacists and family pharmacies.」
Continuing its initiatives in home healthcare and family pharmacist and family pharmacy functions. - FY2017-Q3RestatedAnnual report
「The Group is promoting home healthcare initiatives and the provision of services as family pharmacies and family pharmacists, while appropriately responding to the revision of dispensing fees implemented in April 2016, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and the provision of family pharmacy and family pharmacist functions. - FY2017-Q2RestatedAnnual report
「The Group is promoting home healthcare initiatives and the provision of services as family pharmacies and family pharmacists, while appropriately responding to the revision of dispensing fees implemented in April 2016, as a community pharmacy supporting the health of local residents in various ways.」
Continuing its initiatives in home healthcare and family pharmacy and family pharmacist functions. - FY2017-Q1RestatedAnnual report
「As a community pharmacy supporting the health of local residents in various ways, the company is promoting home healthcare initiatives and the provision of services as a family pharmacy and family pharmacist.」
Continuing its home healthcare initiatives. - FY2016First statedAnnual report
「Focusing on promoting the use of generic drugs and home healthcare initiatives, the company made steady progress in obtaining dispensing technical fees.」
Linking the promotion of generic drug use and home healthcare services to the acquisition of dispensing technical fees and community pharmacy functions.